-
Lepu Scientech’s ScienCcrown TAVR System Earns NMPA Medical Device License
•
Lepu Scientech Medical Technology (Shanghai) Co., Ltd (HKG: 2291), a leading China-based medical technology company, has announced that it has received a medical device license from the National Medical Products Administration (NMPA) for its innovative ScienCcrown transcatheter implantable aortic valve system. This development marks a significant milestone in the advancement…
-
Lepu Scientech Secures NMPA Approval for MemoSORB Biodegradable Atrial Septal Defect Occluder
•
Lepu Scientech Medical Technology (Shanghai) Co., Ltd. (HKG: 2291) has announced that it has received a medical device license from China’s National Medical Products Administration (NMPA) for its innovative MemoSORB biodegradable atrial septal defect occluder. This cutting-edge device offers significant advantages over traditional nitinol occluders by markedly reducing inflammatory responses,…
-
Lepu Scientech Secures NMPA Approval for RF Lance, Advancing Atrial Septal Puncture Technology
•
Lepu Scientech Medical Technology (Shanghai) Co., Ltd (HKG: 2291), a leading medical technology company based in China, has announced that it has obtained a medical device license from the National Medical Products Administration (NMPA) for its RF Lance, a novel disposable radiofrequency atrial septal puncture needle. This product is designed…
-
Lepu ScienTech Reports 33% Revenue Growth in 2023 Interim Report
•
Lepu ScienTech Medical Technology (Shanghai) Co., Ltd, (HKG: 2291) a China-based medical technology company, has released its 2023 interim report, showcasing significant financial growth. The company reported revenues of RMB 165.9 million, marking a 33.0% increase year-on-year (YOY). Net profits also saw a substantial rise, surging by 213.7% YOY to…
-
LEPU ScienTech Medical Technology Sets IPO Price Range Ahead of Hong Kong Listing
•
China-based LEPU ScienTech Medical Technology (Shanghai) Co., Ltd is gearing up for an initial public offering (IPO) on the Hong Kong Stock Exchange. The company plans to issue 22.46 million shares at a price range of HKD 29.15 (USD 3.71) to HKD 31.45 (USD 4.01) per share, potentially raising up…
